Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P-fimbrial lectin adhesins, primarily the PapG protein, are critical virulence factors located at the distal tips of P-pili (pyelonephritis-associated pili) in uropathogenic Escherichia coli (UPEC) [1, 5]. These adhesins function as lectins that specifically recognize and bind to the Gal(alpha1-4)Gal carbohydrate moiety found in the P-blood group antigens and globoseries glycolipids on host cell surfaces [1, 12]. This interaction is a critical first step in the pathogenesis of upper urinary tract infections, as it allows UPEC to colonize the renal pelvis and kidney parenchyma, leading to acute pyelonephritis [16]. There are three main alleles of PapG (I, II, and III), with PapG-II being the most prevalent in human pyelonephritis cases due to its high affinity for globoside (Gb4) in the human kidney [6]. Beyond adhesion, PapG has been shown to protect the bacteria from neutrophil bactericidal activity, further contributing to its role in immune evasion [7]. Because these adhesins are vital for establishing infection but not for bacterial survival, they are considered prime targets for anti-virulence strategies [14]. Therapeutic approaches include synthetic galabiose-based inhibitors that competitively block the binding site and vaccines like the PapDG subunit vaccine designed to elicit protective antibodies [1, 9]. These anti-adhesive molecules offer a promising alternative to traditional antibiotics, potentially reducing the selective pressure for drug resistance while specifically targeting pathogenic strains [3, 14].
Inhibition of bacterial attachment to host uroepithelial cells by competitively binding to Gal(alpha1-4)Gal-containing glycolipid receptors.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P-fimbrial lectin adhesin (PapG).